Relay Therapeutics’ RLY-2608 Shows Promise in Breast Cancer Trials
Company Announcements

Relay Therapeutics’ RLY-2608 Shows Promise in Breast Cancer Trials

Relay Therapeutics ( (RLAY) ) just unveiled an announcement.

Relay Therapeutics has revealed promising interim clinical data for RLY-2608, a novel treatment for PI3Kα-mutated, HR+, HER2- advanced breast cancer. The drug, an allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, showed a median progression-free survival of 9.2 months in heavily pre-treated patients. With favorable tolerability and significant tumor reduction observed, the data support the planned initiation of a pivotal study in 2025. Relay Therapeutics is also advancing with triplet regimens, including one with Pfizer’s atirmociclib, aiming for global commercialization partnerships to focus on their portfolio.

Learn more about RLAY stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyRelay Therapeutics price target raised to $20 from $19 at H.C. Wainwright
TipRanks Auto-Generated NewsdeskRelay Therapeutics Reports Q3 2024 Results and Advances
TheFlyRelay Therapeutics reports Q3 EPS (63c), consensus (77c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App